Tirzepatide Vials — 5mg / 10mg / 15mg / 20mg / 40mg / 60mg

Tirzepatide is a 39-amino-acid dual agonist that binds both the GIP and GLP-1 receptors from a single peptide backbone, with a C20 fatty-diacid moiety that extends its half-life in solution. Supplied as a sterile lyophilised powder in 20mg, 40mg and 60mg vials, verified to 99%+ purity by RP-HPLC and confirmed by mass spectrometry. All three vial sizes are held in UK stock and dispatch the same day when ordered by 1pm, Monday to Friday.

Classification: Tirzepatide (LY3298176) — a synthetic 39 amino-acid dual-agonist peptide with a C20 fatty-diacid moiety, based on the native GIP sequence with modifications enabling GLP-1 receptor activity.

In vitro, Tirzepatide is used to characterise co-activation of the GIP and GLP-1 receptors — including cAMP accumulation, β-arrestin recruitment and receptor-bias studies. It is often used as a comparator peptide when characterising newer molecules such as Retatrutide or Cagrilintide combinations.

This summary describes published preclinical and, where applicable, clinical research. It is not a medical claim and does not describe or endorse any human use of the compound as sold by Peptides UK 4U.

Published research characterises tirzepatide as a dual agonist at the GIP and GLP-1 receptors, with reported biased signalling at the GLP-1 receptor relative to native GLP-1. Preclinical and clinical literature examines the combined incretin signalling profile that distinguishes tirzepatide from single-receptor GLP-1 analogues.

Reconstitute with bacteriostatic water in a sterile environment. The C20 fatty-diacid modification gives good stability in solution; prepare working aliquots to minimise repeated freeze-thaw cycles.

Storage & stability

• Lyophilised vials: store below -18°C, protected from light.
• Reconstituted solution: refrigerate at 2–8°C.
• Avoid repeated freeze-thaw cycles to preserve peptide integrity.

For in vitro research use only. We do not provide preparation, dosing or usage guidance.

Peptide Type

Dual receptor agonist (GIP / GLP-1)

Sequence length

39 amino acids

Molecular weight

≈4,813 Da

Form

Lyophilised powder

Quantity

20mg, 40mg or 60mg per vial

Purity

99%+ by RP-HPLC + MS

Solubility

Water / bacteriostatic water

CAS

2023788-19-2

Certificate of Analysis: Batch-specific COA available. View COAs.

• Coskun T et al., Molecular Metabolism 18:3–14 (2018) — LY3298176 discovery
• Frías JP et al., NEJM 385(6):503–515 (2021) — SURPASS-2 study
• Jastreboff AM et al., NEJM 387(3):205–216 (2022) — SURMOUNT-1 study

References are provided for educational context. Citation does not imply endorsement of any specific use.